Ellinghorst IR compiles independent consensus forecasts of UCB based on the financial estimates of various analysts covering UCB.

In order to provide meaningful data only regularly updated or reiterated estimates are included in the consensus. The tables below are based on the estimates of 18 different brokers. See the list of analysts and their contact details here

If you wish to be informed whenever we have updated consensus, simply send an e-mail to This email address is being protected from spambots. You need JavaScript enabled to view it. quoting "consensus email alert" as subject.  

 ucb

UCB FY Consensus Product Sales Estimates (Average)

In € million 2017a 2018e 2019e 2020e  2021e  2022e  2023e
Cimzia 1,424 1,459 1,500 1,512 1,496 1,456 1,406
Vimpat 976 1,060 1,183 1,293 1,368 1,025 734
Neupro 314 330 346 358 323 276 240
Briviact 87 160 232 295 354 409 476
Keppra 778 743 706 668 618 579 523

 

UCB FY Consensus Earnings Estimates (Average)

In € million 2017a 2018e 2019e 2020e 
Net Sales  4,182 4,291  4,483  4,630 
Revenue  4,530 4,556 4,734 4,874
Recurring EBIT 1,130  1,100 1,186 1,246
Recurring EBITDA 1,375  1,330 1,409 1,469
Net Profit   753 752 835 892
Core EPS (€) 4.82  4.53 4.93 5.23

 

UCB FY Consensus Product Sales Estimates (Median)

In € million 2017a 2018e 2019e 2020e  2021e  2022e  2023e
Cimzia 1,424 1,461 1,512 1,527 1,521 1,406 1,373
Vimpat 976 1,060 1,172 1,269 1,355 1,023 703
Neupro 314 328 345 362 322 266 226
Briviact 87 156 232 303 370 418 488
Keppra 778 744 695 658 610 577 537

 

UCB FY Consensus Earnings Estimates (Median)

In € million 2017a 2018e 2019e 2020e 
Net Sales  4,182 4,283  4,481  4,661 
Revenue  4,530 4,543 4,725 4,891
Recurring EBIT 1,130  1,084 1,178 1,257
Recurring EBITDA  1,375 1,325 1,418 1,482
Net Profit  753  750 816 905
Core EPS (€)  4.82 4.57 4.97 5.35

Downloads:
UCB FY 2017 Consensus (Excel)
UCB FY P&L Consensus ( PDF )
UCB FY Product Sales Consensus (PDF)  

Last updated: 11 May, 2018



Check out UCB's new IR Apps: 

App Apple Store

App Google Play

 

Disclaimer:

This document has been compiled by Ellinghorst IR Ltd. for information purposes only and is not intended to constitute investment advice. It is based on estimates and forecasts of various analysts regarding revenues, earnings and business developments of the relevant company. Such estimates and forecasts cannot be independently verified by reason of the subjective character. Ellinghorst IR Ltd. gives no guarantee, representation or warranty and is not responsible or liable as to its accuracy and completeness. Ellinghorst IR Ltd. has not commented and will not comment on any of the individual financial forecasts used to generate the information contained herein.